Intended for healthcare professionals

Rapid response to:

Practice Clinical Updates

Acute covid-19 and multisystem inflammatory syndrome in children

BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n385 (Published 01 March 2021) Cite this as: BMJ 2021;372:n385

Read our latest coverage of the coronavirus outbreak

Rapid Response:

Re: Acute covid-19 and multisystem inflammatory syndrome in children

Dear Editor

I read this observation of Andrew Bamji with interest [1]:

“I think this is a story of the blind men and the elephant; different observers are seeing slightly different presentations, giving them different names but not appreciating that they are all the same thing, so perhaps this article will help to bring together the different syndromes under one name.”

In a pair of resppnses in 2019 I remarked on the fact that Bexsero Men B vaccine was said in a patient information leaflet to be associated with Kawasaki disease in up to 1 in 1,000 doses and since infants were given 3 this might result in a 3 in 1,000 risk: I further calculated that at the time this might have resulted in an additional 7,000 cases of Kawasaki disease nationally since the product was introduced to the infant schedule in 2015 [2,3]. I therefore note with concern that a Men B vaccine is to be used in the comparator group for trials of their Covid vaccine in children [4,5,6]. Might we just possibly get confusing results?

[1] Andrew Bamji, ‘ Re: Acute covid-19 and multisystem inflammatory syndrome in children’, 7 March 2021, https://www.bmj.com/content/372/bmj.n385/rr-0

[2] John Stone, 'An argument already lost by default?', 22 November 2019, https://www.bmj.com/content/367/bmj.l6447/rr

[3] John Stone, 'Re: An argument already lost by default?', 22 November 2019, https://www.bmj.com/content/367/bmj.l6447/rr-2

[4] https://covid19vaccinetrial.web.ox.ac.uk/files/cov006participantinformat...

[5] Janet Menage, ‘Re: What value the evidence from child trials?’, 18 February 2021, https://www.bmj.com/content/372/bmj.n414/rr-2

[6] John Stone, ‘‘Re: What value the evidence from child trials?’, 18 February 2021, https://www.bmj.com/content/372/bmj.n414/rr-3

Competing interests: AgeofAutism.com, an on-line daily journal, concerns itself with the potential environmental sources for the proliferation of autism, neurological impairment, immune dysfunction and chronic disease. I receive no payment as UK Editor. I also moderate comments for the on-line journal ‘The Defender’ for which I am paid. I am also a member of the UK Medical Freedom Alliance

09 March 2021
John Stone
UK Editor
Ageofautism.com
London N22